INTRODUCTION: Cerebral palsy is the most common cause of physical disability in children.
Spasticity is a disabling clinical symptom that is prevalent among patients suffering from …

One of the main goals when treating spasticity is to relieve pain and improve function.
Intramuscular injection of botulinum toxin type A (BTX‐A) has gained widespread …

Introduction Spasticity has been considered to be a main contributor to both the impairment
of function as well as posture in children with cerebral palsy (CP). Patterns of upper limb …

Objectives In the last 2 decades, BTX-A is increasingly being used in the management of
spasticity in children with Cerebral Palsy (CP) and there is no doubt about its effect on range …

Purpose The aim of this study was to assess the effectiveness of long-term therapy with
multiply botulinum neurotoxin (BoNT) injections. Methods In 2004–2010, 60 children with …

BACKGROUND: To assess treatment effect of lower limb botulinum toxin type A (BTX-A) in
combination with physiotherapy approaches on gross motor functions in children with …

Objective: To evaluate whether botulinum toxin type A injections improve upper limb function
in children with cerebral palsy. Methods: An extensive search was carried out in PUBMED …

Objectives To observe the dose–response relationship of intramuscular injections of
botulinum toxin A (BTX-A) in the spastic cerebral palsy. Methods One hundred fifty cases …

We prospectively studied the medium‐term effects of botulinum toxin type A (BTX‐A)
treatment in 197 children with cerebral palsy. Between one and four target muscles were …

Botulinum toxin A is widely used for spasticity management in children with cerebral palsy,
although outcomes are unpredictable. The aim of this study was to identify criteria for …